What BeOne does

BeOne Medicines (formerly BeiGene) is a global oncology company that discovers, develops, manufactures, and commercializes cancer therapeutics. It sells specialty oncology drugs to hospitals, hematologists, and oncologists across more than 25 countries, with commercial operations in the United States, China, Europe, and other markets supported by a specialty field sales force, inside sales team, and channel partners. The company also generates licensing and royalty income, most notably from the 2024 BMS license of MAT2A and CK1α assets, and it out-licensed tislelizumab development and commercialization rights to Novartis in major ex-US markets in 2021.

The company's commercial portfolio centers on four differentiated oncology assets: BRUKINSA, a BTK inhibitor approved across CLL, MCL, WM, FL, and MZL with documented superiority over ibrutinib in the head-to-head ALPINE trial; TEVIMBRA, a PD-1 inhibitor approved in multiple solid tumor settings; BEQALZI (sonrotoclax), a BCL2 inhibitor that received FDA accelerated approval for relapsed/refractory mantle cell lymphoma; and ZIIHERA, a HER2-targeted bispecific antibody. The underlying R&D platform spans multiple modalities — small molecules, monoclonal antibodies, antibody-drug conjugates (ADCs), bispecifics, trispecifics, and the in-house CDAC protein-degrader platform. BeOne's pipeline includes more than 50 active programs with 15+ new molecular entities entered into the clinic in the last 18 months, and management plans to advance 8-10 additional NMEs per year.

The business model is a hybrid of direct specialty-pharma commercialization in major markets and partnership/royalty economics in territories where it lacks its own infrastructure. BeOne is headquartered in Basel, Switzerland (after a 2026 redomicile from the Cayman Islands), retains major operations in Beijing and Fort Lee, NJ, employs more than 10,000 people globally, and is triple-listed on NASDAQ, the Hong Kong Stock Exchange, and the Shanghai Stock Exchange STAR Market. The company is free cash flow positive with $4.85B in cash and equivalents as of the most recent disclosure, giving it capital to self-fund its unusually large pipeline while continuing buybacks and selective external investments such as the Terremoto Biosciences Series C participation.

Name

BeOne

Legal name

BeOne Medicines Ltd.

Website

https://beonemedicines.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

BeOne Medicines is a global oncology company that develops and commercializes cancer therapies (BRUKINSA, TEVIMBRA, BEQALZI, ZIIHERA) sold to hematologists and oncologists across 25+ countries. Its pipeline spans small molecules, bispecifics, ADCs, and protein degraders.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Oncology Biosimilars (HLAAAHAG), Medical Oncology (HLAKAFAB), Transplant & Immunosuppression Specialty Pharmaceuticals (HLAIACAJ), Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown) (HLAAADAC)

Keywords

• Oncology drug development
• BTK inhibitor therapy
• Immuno-oncology biologics
• Antibody drug conjugates
• Targeted cancer therapeutics

Headquarters

HQ city

Klein-basel

HQ country

Switzerland

HQ region

Europe

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical product sales — BRUKINSA (zanubrutinib): Flagship BTK inhibitor generating $3.9B in FY2025 (+49% YoY) and $1.1B in Q1 2026 (+38% YoY); largest revenue contributor and global revenue leader among BTK inhibitors.
2. Pharmaceutical product sales — TEVIMBRA (tislelizumab): Anti-PD-1 monoclonal antibody; generated $206M in Q1 2026 with sBLA Priority Review for HER2+ GEA combination.
3. Pharmaceutical product sales — BEQALZI (sonrotoclax): BCL2 inhibitor approved May 2026 by U.S. FDA for R/R mantle cell lymphoma; Truist projects $300–400M sales for MCL indication and >$3.4B peak potential in CLL.
4. Licensing and milestone income — ZIIHERA / zanidatamab: Royalty and milestone income from partnered assets including zanidatamab co-developed with Jazz Pharmaceuticals and Zymeworks (tiered royalties 10–20% on net sales), with up to $440M in milestone potential across U.S./EU/Japan/China approvals.
5. Strategic option/license fees — pipeline assets: Upfront, option exercise, and milestone payments from out-licensing and in-licensing deals (e.g., Huahui Health HH160: $20M upfront + $100M option exercise + up to $1.9B milestones plus tiered royalties).

Go-to-market motion3 records

Distribution channels5 records

Marketing channels9 records

Core offering

BeOne Medicines is a global oncology biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative cancer therapies. Its commercial portfolio includes three proprietary drugs — BRUKINSA (zanubrutinib, BTK inhibitor), TEVIMBRA (tislelizumab, PD-1 inhibitor), and BEQALZI (sonrotoclax, BCL2 inhibitor) — plus ZIIHERA (zanidatamab-hrii, HER2 bispecific antibody) co-developed with Jazz Pharmaceuticals. The company operates a global specialty oncology field sales force in 25+ countries and runs proprietary research platforms spanning protein degraders (CDACs), antibody-drug conjugates, and bispecific/trispecific antibodies.

Product overview

BeOne Medicines operates a platform-plus-portfolio architecture in oncology, anchored by three commercial products (BRUKINSA, TEVIMBRA, and BEQALZI) plus the partnered ZIIHERA, supported by multiple research platforms and a deep pipeline of 15+ new molecular entities (NMEs) BeOne advanced into the clinic in the past 18 months. BRUKINSA (zanubrutinib), the next-generation BTK inhibitor and global revenue leader in its class, sits at the center of a hematology franchise that pairs with BEQALZI (sonrotoclax), the next-generation BCL2 inhibitor approved in May 2026 for R/R MCL, and TEVIMBRA (tislelizumab), the PD-1 checkpoint inhibitor used across esophageal, gastric, and other solid tumors. These three commercial assets are extended by ZIIHERA (zanidatamab-hrii), a HER2-targeted bispecific antibody developed with Jazz Pharmaceuticals and Zymeworks, now advancing in HER2+ gastroesophageal adenocarcinoma. The platform dimension of BeOne's offering centers on three proprietary research modalities: protein degradation via CDACs (exemplified by BTK degrader tacabrutideg/BGB-16673), enhanced antibody-drug conjugates (ADCs such as BG-C9074 and a CEA ADC), and bispecific antibodies (including GPC3x4-1BB BGB-B2033 and the ZIIHERA franchise), all wrapped around clinical programs, a BeCollective HCP investigator network, a patient support program, an expanded access program, and the BeOne Care Foundation for community outreach.

Differentiator

Problem solved

Functional benefit

Brands

• BRUKINSA: BRUKINSA (zanubrutinib) is BeOne's flagship BTK inhibitor, generating $3.9 billion in FY2025 revenue; global revenue leader among BTK inhibitors for CLL/SLL treatment.
• BEQALZI
• TEVIMBRA
• ZIIHERA

Products and services

• BRUKINSA (zanubrutinib) BeOne's flagship next-generation irreversible BTK inhibitor, an oral small-molecule drug approved globally for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, Waldenstrom's macroglobulinemia, follicular lymphoma, and marginal zone lymphoma. Generated $3.9B in FY2025 revenue and is the global revenue leader among BTK inhibitors.
• TEVIMBRA (tislelizumab) BeOne's anti-PD-1 immune checkpoint inhibitor monoclonal antibody, approved for multiple solid tumor indications including esophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, and other tumor types. Used in combination with ZIIHERA and chemotherapy for first-line HER2-positive gastroesophageal adenocarcinoma. Generated $206M in Q1 2026 revenue.
• BEQALZI (sonrotoclax) BeOne's next-generation BCL2 inhibitor; received U.S. FDA accelerated approval in May 2026 as the first and only BCL2 inhibitor specifically approved for relapsed/refractory mantle cell lymphoma. BeOne's third commercial product. Phase 1/2 data showed 52% ORR and 16% CR rate in R/R MCL, with projected peak CLL sales potential exceeding $3.4 billion per Truist.
• ZIIHERA (zanidatamab-hrii) HER2-targeted bispecific antibody co-developed with Jazz Pharmaceuticals and Zymeworks, approved for HER2-positive biliary tract cancer. Phase 3 HERIZON-GEA-01 trial demonstrated 26.4-month median overall survival when combined with TEVIMBRA and chemotherapy as first-line therapy in HER2+ gastroesophageal adenocarcinoma, leading to FDA Priority Review for the sBLA in April 2026.
• Patient Support Program
• Expanded Access Program BeOne's Expanded Access Program enables eligible patients with serious or life-threatening conditions to access BeOne's investigational oncology medicines outside of clinical trials when no comparable alternative therapy is available.

Quantifiable outcome

• BRUKINSA PFS 71.8% vs 31.0% for bendamustine-rituximab at 78 months
• +5 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Eleven partnerships are on record, tiered minor, core and flagship.

• Blood Cancer UnitedminorGTM or Marketing Partner · 24 June 2026Expanded three-year patient advocacy partnership announced June 2026 with $5M in funding over three years, building on more than $3.2M invested since 2022. Programs include expert-led educational webcasts, a Clinical Trial Support Center, and Light The Night community events for people impacted by blood cancer. Aligned with Blood Cancer United's goal of enabling patients to gain more than one million years of life by 2040.
• Cytovation ASAminorStrategic or Co-development Partner · 18 May 2026Clinical supply agreement under which BeOne supplies tislelizumab (TEVIMBRA) to support a Cytovation Phase 2 study of getacatetide (CY-101) in combination with the PD-1 inhibitor in patients with metastatic colorectal cancer, focusing on β-catenin-driven immune exclusion in liver metastases.
• Senhwa BiosciencesminorStrategic or Co-development Partner · 5 May 2026Senhwa is conducting a global, multi-center clinical trial evaluating pidnarulex (CX-5461) in combination with BeOne's tislelizumab (TEVIMBRA) across multiple advanced solid tumors including pancreatic, colorectal, and melanoma; Senhwa has also submitted an IND application to U.S. FDA. BeOne supplies the PD-1 inhibitor for the combination.
• Huahui HealthcoreStrategic or Co-development Partner · 30 April 2026Global exclusive option, license and collaboration agreement for HH160, a preclinical trispecific antibody targeting PD-1, CTLA-4, and VEGF-A. BeOne pays $20M upfront, an additional $100M upon option exercise, and up to $1.9B in development, regulatory, and sales milestones plus tiered royalties on net sales. BeOne receives exclusive worldwide rights to develop, manufacture, and commercialize HH160 leveraging Huahui's PolyBoost multispecific antibody platform. BeOne may also participate in Huahui's future financing rounds.
• Memorial Sloan Kettering Cancer CenterminorStrategic or Co-development Partner · 4 February 2026MSKCC is the sponsor of the first immunotherapy clinical trial in sub-Saharan Africa, a Phase II study targeting patients with mismatch-repair deficient colorectal cancer in Nigeria. BeOne supplies the PD-1 inhibitor tislelizumab (TEVIMBRA). Partners include Obafemi Awolowo University, Lagos University Teaching Hospital, and Medserve.
• InnornaminorStrategic or Co-development Partner · 20 January 2026Strategic partnership with Hong Kong-headquartered Innorna to accelerate development and commercialization of Innorna's mRNA pipeline. Innorna has a proprietary lipid nanoparticle (LNP) platform with over 6,000 structurally diverse ionizable lipids and has secured FDA Rare Pediatric Disease and Orphan Drug Designations for four protein replacement therapies.
• WEHI (Walter and Eliza Hall Institute of Medical Research)minorStrategic or Co-development Partner · 18 September 2025Research collaboration supporting BeOne's global clinical development and fostering international research collaborations within the Victoria biomedical sector.
• Jazz PharmaceuticalsflagshipStrategic or Co-development PartnerCo-development and commercialization partnership for ZIIHERA (zanidatamab-hrii) and the HERIZON-GEA-01 program. The Phase 3 HERIZON-GEA-01 trial of zanidatamab combinations enrolled 914 patients across 30+ countries and ~225–300 sites; FDA Priority Review granted April 2026 with PDUFA date August 25, 2026. Jazz owns the sBLA in its territories; BeOne retains commercialization rights and earns tiered royalties/royalties on ZIIHERA net sales. BeOne and Jazz are also listed as licensees to Zymeworks with tiered royalty obligations.
• ZymeworkscoreOEM/ Whitelabel/ Licensing PartnerLicensor relationship under which BeOne (alongside Jazz Pharmaceuticals) owes Zymeworks tiered royalties of 10–20% on annual net sales of ZIIHERA (zanidatamab). Up to $440M in milestone payments tied to U.S., EU, Japan, and China regulatory approvals. The royalty stream was used by Zymeworks to secure a $250M non-recourse royalty-backed note financing from Royalty Pharma in March 2026, secured by 30% of the worldwide tiered royalties from BeOne and Jazz.
• Ensem TherapeuticsminorStrategic or Co-development PartnerAcquisition of CDK2 inhibitor BG-68501 through a $1.33B deal with Ensem Therapeutics; program subsequently discontinued in May 2026 pipeline review (Phase 1 termination).
• CSPC Zhongqi Pharmaceutical TechnologyminorStrategic or Co-development PartnerLate-2024 pact under which BeOne acquired assets (MAT2A inhibitor BG-89894 subsequently discontinued in May 2026); multi-modality approach retained in target area.

Scale indicators13 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Novartis: Major oncology incumbent with radioligand therapy (Pluvicto), CDK4/6 inhibitor (Kisqali), and broad hematology presence — competing with BeOne's CDK4 inhibitor BGB-43395 in HR+/HER2- breast cancer and broader solid tumor pipeline.
• Bristol-Myers Squibb: Major oncology incumbent with PD-1 inhibitor Opdivo and hematology assets that compete across both solid tumor (where TEVIMBRA competes) and hematology (BTK class via ibrutinib partnership heritage) franchises.
• Roche: Global oncology leader with HER2 franchise (Herceptin, Kadcyla, Phesgo) that overlaps with BeOne's ZIIHERA + TEVIMBRA HER2+ gastroesophageal program, and broad PD-1/PD-L1 presence competing with TEVIMBRA.
• Johnson & Johnson (Innovative Medicine): Co-markets Imbruvica (with AbbVie and Pharmacyclics) and has a deep oncology portfolio spanning hematology and solid tumors that overlaps with multiple BeOne franchise areas including multiple myeloma and prostate cancer adjacencies.
• Pfizer: Diversified oncology incumbent with established hematology presence (including prior co-marketing of ibrutinib) and pipeline assets that compete across multiple BeOne indications; also operates global commercial infrastructure in 25+ countries similar to BeOne's footprint.

Direct peers

• Incyte: Hematology-focused oncology company with JAK inhibitor Jakafi and growing portfolio of B-cell malignancy therapies; competes in similar hematology indications to BRUKINSA and BEQALZI and has comparable mid-cap oncology commercial scale.
• AstraZeneca: Markets Calquence (acalabrutinib), a leading BTK inhibitor in CLL and MCL that directly competes with BeOne's flagship BRUKINSA; AstraZeneca's broader oncology portfolio also overlaps with BeOne's solid tumor programs.
• Eli Lilly (Loxo@Lilly): Markets Jaypirca (pirtobrutinib), the first non-covalent BTK inhibitor that serves as the head-to-head comparator in BeOne's tacabrutideg Phase 3 program and competes in the same R/R CLL/SLL setting as BRUKINSA.
• Jazz Pharmaceuticals: BeOne's commercial partner on ZIIHERA (zanidatamab) for ex-BeOne territories — also operates a specialty oncology and hematology commercial franchise overlapping with BeOne's footprint in HER2-positive cancers and CNS oncology adjacencies.
• AbbVie: Markets Imbruvica (ibrutinib, first-generation BTK inhibitor) and Venclexta (BCL2 inhibitor) — BeOne's principal direct competitors in both BTK and BCL2 hematology franchises where BRUKINSA and BEQALZI are positioned.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/beonemedicines

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BeOne